Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Nausea is common when starting GLP-1 medications but typically improves within 48 weeks
In these populations, GLP-1 medications may: Suppress appetite in ways that destabilize recovery Mask symptoms without addressing underlying drivers Increase psychological distress related to food, weight, or control Any consideration of GLP-1 use should involve careful medical oversight, psychological evaluation, and ongoing monitoring
However, published data allows a directional comparison of the most common GI events: Adverse Event Retatrutide (12 mg) Semaglutide 2.4 mg (STEP trials) Tirzepatide 15 mg (SURMOUNT trials) Nausea ~46% ~44% ~31% Diarrhea ~33% ~30% ~23% Vomiting ~22% ~24% ~12% Constipation ~17% ~24% ~12% Important caveat: These numbers come from different trial populations and cannot be directly compared
The round was led by Bain Capital Ventures (BCV) Capital Private Equity, with participation from multiple new and existing investors
What this means before you click buy Confirm with a registered doctor or pharmacist that retatrutide is appropriate for your medical history, because the product is unregistered and carries unknown purity risk
GLP-1RAs and dual incretin agonists have been shown to reduce adipocyte hypertrophy and stimulate the activation of BAT, thereby enhancing energy expenditure and metabolic function
US$ 20.20
US$ 29.74
US$ 23.70
US$ 28.83
US$ 22.53
